Roche TIGIT monoantigen has been approved in China for clinical joint Tecentriq treatment of esophageal squamous cancer.

TIGIT is expressed in a variety of immune cells, including CD8-T cells, CD4-T cells, and NK cells, and is a CD226 co-stimulating receptor-specific negative regulator.
CD155, which is highly expressed on the surface of tumor cells, is a high affinity liant for TIGIT, and once combined with TIGIT on the surface of NK and T cells, the lethal effect of T cells on tumor cells is inhibited.
TIGIT is one of the most promising and promising targets for tumor immunotherapy.
clinical results show that anti-TIGIT antibodies as monotherapy or combination anti-PD-1/PD-L1 antibody drugs have shown certain safety and anti-tumor effectiveness, especially combination therapy is expected to play a synergistic role.
, several clinical studies related to anti-TIGIT monoclonal antibody drugs are being carried out abroad, but no varieties have been approved.
esophageal cancer is the seventh most common cancer in the world and the sixth leading cause of death.
5-year relative survival rate of patients with metastatic esophageal cancer was generally less than 8%.
two most common types of esophageal cancer are squamous cell carcinoma and adenocarcinoma, accounting for 90% and 10% of all esophageal cancers, respectively.
about 572,000 new confirmed cases each year, and about half a million people die from esophageal cancer.
most patients are diagnosed at a late stage, affecting their daily lives, including diet.
incidence of esophageal cancer in Asia, with more than 444,000 confirmed cases per year, accounting for about 80 per cent of global esophageal cancer cases.
.